PDCD1 and neoplasm: The combination therapy between these Ag-citrate NP and anti-PD1 antibodies induce cytotoxicity by ROS production and the secretion of cytokines that in turn induced an immune response, mostly by recruitment of CD8+ T cells to tumor sites.88